📊 IOBT Key Takeaways
Is IO Biotech, Inc. (IOBT) a Good Investment?
IO Biotech is a pre-revenue pharmaceutical company with severe financial distress, burning $61.4M in operating cash flow with only $30.7M in cash reserves, indicating a runway of approximately 6 months. The company's negative net income of -$57.0M, combined with a debt-to-equity ratio of 18.29x and stockholders' equity of only $911K, suggests imminent solvency concerns and substantial dilution risk for existing shareholders.
IO Biotech’s fundamentals are very weak: the company has no reported revenue, continues to post large operating and net losses, and is consuming cash at a rate that appears unsustainable relative to its cash balance. While liquidity ratios look acceptable on the surface, equity is nearly exhausted and leverage is extremely high, making the business heavily dependent on external funding rather than internally generated financial strength.
Why Buy IO Biotech, Inc. Stock? IOBT Key Strengths
- Adequate short-term liquidity with current ratio of 2.01x providing temporary operational flexibility
- Substantial cash position of $30.7M relative to total assets, though insufficient relative to burn rate
- No insider selling activity in last 90 days suggests management confidence, though absence of insider buying is notable
- Cash and equivalents of $30.66M provide some near-term operating flexibility
- Current and quick ratios of 2.01x indicate near-term liabilities are currently covered by liquid assets
- Diluted EPS improved year over year, suggesting some loss-per-share moderation
IOBT Stock Risks: IO Biotech, Inc. Investment Risks
- Severe cash burn of $61.4M annually with only 6 months of runway at current rate, creating critical funding risk
- Pre-revenue status with no commercial product monetization despite operating as a pharmaceutical company
- Extremely high leverage with debt-to-equity of 18.29x and minimal equity cushion of $911K, indicating bankruptcy risk if cash depletes
- Negative interest coverage of -215.6x shows inability to service debt from operations
- Operating losses of -$65.1M demonstrate fundamental business model failure without path to profitability
- No revenue base means the business is not yet demonstrating commercial traction or self-funding capacity
- Operating cash outflow of $61.37M and free cash flow of -$61.43M imply severe cash burn relative to available cash
- Stockholders’ equity of just $0.91M and debt/equity of 18.29x indicate a highly fragile balance sheet
Key Metrics to Watch
- Monthly cash burn rate and remaining runway to assess immediate solvency timeline
- Clinical trial progress and regulatory milestones that could support future revenue potential
- Additional financing activities and dilution impact on existing shareholders
- Operating cash flow trajectory and quarterly burn rate changes
- Quarterly cash burn versus cash balance/runway
- Progress toward revenue generation and reduction in operating losses
IO Biotech, Inc. (IOBT) Financial Metrics & Key Ratios
💡 AI Analyst Insight
Strong liquidity with a 2.01x current ratio provides a solid financial cushion.
IOBT Profit Margin, ROE & Profitability Analysis
IOBT vs Healthcare Sector: How IO Biotech, Inc. Compares
How IO Biotech, Inc. compares to Healthcare sector averages
Sector benchmarks are approximate industry averages. Actual sector performance may vary.
Is IO Biotech, Inc. Stock Overvalued? IOBT Valuation Analysis 2026
Based on fundamental analysis, IO Biotech, Inc. shows some fundamental concerns relative to the Healthcare sector in 2026.
Note: This is a fundamental analysis based on SEC filings. For P/E ratio, price targets, and market-based valuation, consult financial data providers. This is not investment advice.
IO Biotech, Inc. Balance Sheet: IOBT Debt, Cash & Liquidity
IOBT Revenue & Earnings Growth: 5-Year Financial Trend
5-Year Trend Summary: IO Biotech, Inc.'s revenue has remained relatively flat over the 5-year period, with a 0% decline. The most recent EPS of $-1.98 indicates the company is currently unprofitable.
IOBT Revenue Growth, EPS Growth & YoY Performance
IO Biotech, Inc. Dividends, Buybacks & Capital Allocation
IOBT SEC Filings: Latest 10-K & 10-Q Analysis
Access official SEC EDGAR filings for IO Biotech, Inc. (CIK: 0001865494)
📋 Recent SEC Filings
❓ Frequently Asked Questions about IOBT
What is the AI rating for IOBT?
IO Biotech, Inc. (IOBT) has a Combined AI Rating of STRONG SELL from Claude (STRONG SELL) and ChatGPT (STRONG SELL) with 93% combined confidence, based on fundamental analysis of SEC EDGAR filings.
What are IOBT's key strengths?
Claude: Adequate short-term liquidity with current ratio of 2.01x providing temporary operational flexibility. Substantial cash position of $30.7M relative to total assets, though insufficient relative to burn rate. ChatGPT: Cash and equivalents of $30.66M provide some near-term operating flexibility. Current and quick ratios of 2.01x indicate near-term liabilities are currently covered by liquid assets.
What are the risks of investing in IOBT?
Claude: Severe cash burn of $61.4M annually with only 6 months of runway at current rate, creating critical funding risk. Pre-revenue status with no commercial product monetization despite operating as a pharmaceutical company. ChatGPT: No revenue base means the business is not yet demonstrating commercial traction or self-funding capacity. Operating cash outflow of $61.37M and free cash flow of -$61.43M imply severe cash burn relative to available cash.
What is IOBT's revenue and growth?
IO Biotech, Inc. reported revenue of N/A.
Does IOBT pay dividends?
IO Biotech, Inc. does not currently pay dividends.
Where can I find IOBT SEC filings?
Official SEC filings for IO Biotech, Inc. (CIK: 0001865494) including 10-K, 10-Q, and 8-K reports are available on SEC EDGAR.
What is IOBT's EPS?
IO Biotech, Inc. has a diluted EPS of $-0.86.
How is the AI analysis conducted?
Two independent AI systems — Claude (Anthropic) and ChatGPT (OpenAI) — analyze SEC EDGAR filings including 10-K annual reports and 10-Q quarterly reports. Each AI evaluates financial health, profitability ratios, balance sheet strength, and growth metrics. The combined rating reflects both perspectives for balanced insights.
Is IOBT a good stock to buy right now?
Based on our AI fundamental analysis in April 2026, IO Biotech, Inc. has a STRONG SELL rating with 93% confidence. Review the strengths and risks sections above before making a decision. This is not investment advice.
Is IOBT stock overvalued or undervalued?
Valuation metrics for IOBT: ROE of -6,258.6% (sector avg: 15%), net margin of N/A (sector avg: 12%). Compare these metrics with sector averages to assess valuation.
Should I buy IOBT stock in 2026?
Our dual AI analysis gives IO Biotech, Inc. a combined STRONG SELL rating for 2026. Revenue is data pending, with profitability at or below sector average. Always conduct your own research.
What is IOBT's free cash flow?
IO Biotech, Inc.'s operating cash flow is $-61.4M, with capital expenditures of $58.0K.
How does IOBT compare to other Healthcare stocks?
Vs Healthcare sector averages: Net margin N/A (avg: 12%), ROE -6,258.6% (avg: 15%), current ratio 2.01 (avg: 2).
Is IO Biotech, Inc. carrying too much debt?
IOBT has a debt-to-equity ratio of 18.29x, which is above the Healthcare sector average of 0.6x. However, the current ratio of 2.01 suggests adequate short-term liquidity.